Chimerix, Inc. – NASDAQ:CMRX
Chimerix stock price today
$8.54
+5.07
+146.82%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 21 minutes
Chimerix stock price monthly change
+285.09%
month
Chimerix stock price quarterly change
+285.09%
quarter
Chimerix stock price yearly change
+265.17%
year
Chimerix key metrics
Market Cap | 266.66M |
Enterprise value | 81.88M |
P/E | 0.63 |
EV/Sales | 2.42 |
EV/EBITDA | 0.46 |
Price/Sales | 3.12 |
Price/Book | 0.41 |
PEG ratio | N/A |
EPS | -0.92 |
Revenue | N/A |
EBITDA | -93.19M |
Income | -82.59M |
Revenue Q/Q | -100% |
Revenue Y/Y | -99.87% |
Profit margin | 509.01% |
Oper. margin | -178.53% |
Gross margin | 98.68% |
EBIT margin | -178.53% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeChimerix stock price history
Chimerix stock forecast
Chimerix financial statements
| Jun 2023 | 26K | -18.57M | -71446.15% |
|---|---|---|---|
| Sep 2023 | 11K | -23.98M | -218054.55% |
| Dec 2023 | 4K | -18.16M | -454025% |
| Mar 2024 | 0 | -21.86M |
| Sep 2025 | 2.15K | -24.46M | -1136952.83% |
|---|---|---|---|
| Oct 2025 | 0 | -23.67M | |
| Dec 2025 | 0 | -23.16M | |
| Mar 2026 | 0 | -20.52M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 241085000 | 16.97M | 7.04% |
|---|---|---|---|
| Sep 2023 | 225282000 | 16.97M | 7.54% |
| Dec 2023 | 212774000 | 19.74M | 9.28% |
| Mar 2024 | 194042000 | 19.94M | 10.28% |
| Jun 2023 | -14.34M | 18.52M | -31K |
|---|---|---|---|
| Sep 2023 | -17.93M | 11.87M | 78K |
| Dec 2023 | -14.52M | 28.06M | 62K |
| Mar 2024 | -17.68M | 8.67M | 378K |
Chimerix alternative data
| Aug 2023 | 89 |
|---|---|
| Sep 2023 | 89 |
| Oct 2023 | 89 |
| Nov 2023 | 89 |
| Dec 2023 | 89 |
| Jan 2024 | 89 |
| Feb 2024 | 89 |
| Mar 2024 | 72 |
| Apr 2024 | 72 |
| May 2024 | 72 |
| Jun 2024 | 72 |
| Jul 2024 | 72 |
Chimerix other data
52.26%
-6.55%
of CMRX is owned by hedge funds
102
-14
45.69M
-5.52M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 20000 | 0 |
| May 2023 | 165450 | 0 |
| Sep 2023 | 20000 | 3610 |
| Nov 2023 | 20000 | 0 |
| Feb 2024 | 0 | 6344 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | ANDRIOLE MICHAEL T. director, officer: PRESIDENT AN.. | Common Stock | 1,744 | $1.04 | $1,810 | ||
Sale | LASPALUTO MICHELLE officer: CHIEF FINANCIAL OFFICER | Common Stock | 1,940 | $1.04 | $2,023 | ||
Sale | JAKEMAN DAVID officer: VP OF FINANCE AND ACCO.. | Common Stock | 2,660 | $1.04 | $2,777 | ||
Purchase | MIDDLETON FRED A director | Common Stock | 17,295 | $0.96 | $16,517 | ||
Purchase | MIDDLETON FRED A director | Common Stock | 2,705 | $0.92 | $2,489 | ||
Sale | JAKEMAN DAVID officer: VP of Finance and Acco.. | Common Stock | 3,610 | $0.99 | $3,585 | ||
Purchase | MIDDLETON FRED A director | Common Stock | 20,000 | $0.98 | $19,640 | ||
Purchase | ANDRIOLE MICHAEL T. officer: Chief Business Officer.. | Common Stock | 51,700 | $1.14 | $59,145 | ||
Purchase | SHERMAN MICHAEL A. director, officer.. | Common Stock | 75,015 | $1.12 | $84,092 | ||
Purchase | SHERMAN MICHAEL A. director, officer.. | Common Stock | 11,985 | $1.13 | $13,531 |
| Patent |
|---|
Application MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-- 7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOF Filling date: 4 Aug 2021 Issue date: 14 Jul 2022 |
Application Filling date: 16 Jun 2021 Issue date: 12 May 2022 |
Application Filling date: 29 Jul 2021 Issue date: 10 Mar 2022 |
Application 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-a]PYRIDO[3,4-e]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY Filling date: 24 Jun 2021 Issue date: 20 Jan 2022 |
Application Filling date: 27 Jan 2021 Issue date: 6 Jan 2022 |
Grant Filling date: 11 Oct 2019 Issue date: 20 Jul 2021 |
Grant Filling date: 6 Aug 2019 Issue date: 9 Mar 2021 |
Application MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-- 7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOF Filling date: 21 Sep 2018 Issue date: 3 Sep 2020 |
Application Filling date: 6 Aug 2019 Issue date: 25 Jun 2020 |
Application Filling date: 20 Dec 2019 Issue date: 7 May 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 1 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 5 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Michael A. Sherman (1966) Chief Executive Officer, Pres & Director | $1,110,000 |
Mr. Michael T. Andriole M.B.A. (1973) Chief Bus. Officer, Sec. & Chief Financial Officer | $657,350 |
Chimerix: Dangerous Road, Thesis Intact
Chimerix: Gaining Traction, Cash Runway To 2027
Organigram And Rounding Out My Tax Loss Selling Basket
Chimerix: A Confusing Business Strategy Makes It Unconvincing
Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation
ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas
-
What's the price of Chimerix stock today?
One share of Chimerix stock can currently be purchased for approximately $8.54.
-
When is Chimerix's next earnings date?
Unfortunately, Chimerix's (CMRX) next earnings date is currently unknown.
-
Does Chimerix pay dividends?
No, Chimerix does not pay dividends.
-
How much money does Chimerix make?
Chimerix has a market capitalization of 266.66M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 99.04% to 324K US dollars.
-
What is Chimerix's stock symbol?
Chimerix, Inc. is traded on the NASDAQ under the ticker symbol "CMRX".
-
What is Chimerix's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Chimerix?
Shares of Chimerix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Chimerix's key executives?
Chimerix's management team includes the following people:
- Mr. Michael A. Sherman Chief Executive Officer, Pres & Director(age: 59, pay: $1,110,000)
- Mr. Michael T. Andriole M.B.A. Chief Bus. Officer, Sec. & Chief Financial Officer(age: 52, pay: $657,350)
-
How many employees does Chimerix have?
As Jul 2024, Chimerix employs 72 workers.
-
When Chimerix went public?
Chimerix, Inc. is publicly traded company for more then 12 years since IPO on 11 Apr 2013.
-
What is Chimerix's official website?
The official website for Chimerix is chimerix.com.
-
Where are Chimerix's headquarters?
Chimerix is headquartered at 2505 Meridian Parkway, Durham, NC.
-
How can i contact Chimerix?
Chimerix's mailing address is 2505 Meridian Parkway, Durham, NC and company can be reached via phone at +91 98061074.
Chimerix company profile:
Chimerix, Inc.
chimerix.comExchange:
NASDAQ
Full time employees:
72
Industry:
Biotechnology
Sector:
Healthcare
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
2505 Meridian Parkway
Durham, NC 27713
Durham, NC 27713
CIK: 0001117480
ISIN: US16934W1062
CUSIP: 16934W106
